Literature DB >> 16465689

Clinical trials yield promising results from two adenovirus-based vaccines.

.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16465689

Source DB:  PubMed          Journal:  IAVI Rep        ISSN： 1816-6253


× No keyword cloud information.
  3 in total

1.  Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.

Authors:  Paul Spearman; Spyros Kalams; Marnie Elizaga; Barbara Metch; Ya-Lin Chiu; Mary Allen; Kent J Weinhold; Guido Ferrari; Scott D Parker; M Juliana McElrath; Sharon E Frey; Jonathan D Fuchs; Michael C Keefer; Michael D Lubeck; Michael Egan; Ralph Braun; John H Eldridge; Barton F Haynes; Lawrence Corey
Journal:  Vaccine       Date:  2008-11-07       Impact factor: 3.641

2.  An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice.

Authors:  E S Gabitzsch; Y Xu; S Balcaitis; J P Balint; F R Jones
Journal:  Cancer Gene Ther       Date:  2011-01-14       Impact factor: 5.987

3.  Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice.

Authors:  Maria A Croyle; Ami Patel; Kaylie N Tran; Michael Gray; Yi Zhang; James E Strong; Heinz Feldmann; Gary P Kobinger
Journal:  PLoS One       Date:  2008-10-29       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.